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Abstract
Neo-angiogenesis represents an important factor for the delivery of oxygen and nutrients to a growing tumour, and is
considered to be one of the main pathodiagnostic features of glioblastomas (GBM). Anti-angiogenic therapy by vascular
endothelial growth factor (VEGF) blocking agents has been shown to lead to morphological vascular normalisation
resulting in a reduction of contrast enhancement as seen by magnetic resonance imaging (MRI). Yet the functional
consequences of this normalisation and its potential for improved delivery of cytotoxic agents to the tumour are not
known. The presented study aimed at determining the early physiologic changes following bevacizumab treatment.
A time series of perfusion MRI and hypoxia positron emission tomography (PET) scans were acquired during the first
week of treatment, in two human GBM xenograft models treated with either high or low doses of bevacizumab.
We show that vascular morphology was normalised over the time period investigated, but vascular function was not
improved, resulting in poor tumoural blood flow and increased hypoxia.
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Introduction
Glioblastomas (GBMs) are highly heterogeneous
tumours, characterised by angiogenesis and necrosis.1
In 2009, the FDA approved bevacizumab, a monoclo-
nal antibody against circulating vascular endothelial
growth factor (VEGF), for second line treatment of
patients with recurrent GBM. The accelerated approval
was granted on the basis of two single arm trials, show-
ing strong radiological responses in comparison to his-
torical data,2,3 assessed by the Macdonald criteria.4
However, although progression-free survival (PFS)
was prolonged, bevacizumab treatment did not
improve overall survival (OS), when given alone or in
combination with traditional chemotherapeutic regi-
mens, whether for recurrent or newly diagnosed
GBM.5–7 The radiological response was attributed to
a reduced blood brain barrier (BBB) permeability,
rather than a true anti-tumour effect.8 Several clinical
trials in recurrent GBM have also attempted to com-
bine bevacizumab therapy with alternative chemother-
apeutic regimens.9,10 The phase II BELOB trial,
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for example showed improved OS in patients treated
with a combination of lomustine and bevacizumab.10
Unfortunately, a subsequent randomised phase III trial
did not validate these results, leaving the future of anti-
angiogenic treatment in GBM highly uncertain.11
According to Folkman’s hypothesis, anti-angiogenic
therapy should prevent the formation of new blood
vessels, leading to a nutrient- and oxygen-deprived
tumour that subsequently ceases to progress.12 As
tumour vessels are highly irregular, tortuous and
leaky, the delivery of oxygen and nutrients is inefficient.
Jain et al. proposed that anti-angiogenic therapy may
lead to a transient window of tumour vessel normalisa-
tion, shortly after treatment initiation, with increased
pericyte coverage and a thickening of the basal mem-
brane, resulting in increased blood flow with improved
oxygen and drug delivery.13,14 In GBMs, preclinical
studies have suggested that VEGF receptor 2 blockade
can normalise the tumour vessels transiently by up-
regulating angiopoietin 1 (Ang-1), leading to the stimu-
lation and recruitment of pericytes with an increased
tumour perfusion and decreased hypoxia.15 It has also
been proposed that this normalisation leads to a
decreased interstitial pressure that facilitates drug deliv-
ery and an improved tumour oxygenation that
increases tumour sensitivity to radiation.16,17 In con-
trast, other studies indicate that anti-angiogenic treat-
ment may lead to a reduced drug delivery caused by a
restoration of the BBB.18,19 Support for the former
view is found among a subset of patients treated with
cediranib, a VEGFR tyrosine kinase inhibitor (TKI),
where increased tumour perfusion was observed in
some patients.20–22
The proposed window of vascular normalisation is
expected to occur transiently during the first days of
treatment. In previous studies, our group has shown
that bevacizumab treatment leads to morphological
vessel normalisation without an increase in blood flow
in human GBM patient-derived xenograft (PDX)
models.23,24 Since blood flow was evaluated several
weeks after the initiation of the treatment, the transient
window of vascular normalisation might have been
missed in these studies. We thus designed the present
study to establish whether our clinically relevant PDX
models display such a window of vascular normalisa-
tion or not, by repeatedly assessing perfusion param-
eters during the early courses of bevacizumab
treatment. We used two different models displaying
the properties of a purely angiogenic and a mixed
angiogenic/infiltrative phenotype, closely mimicking
the features of clinical GBM. The animals were treated
with bevacizumab in doses equivalent to their clinical
counterparts or in lower doses to see whether tumour
vessel normalisation represents a dose-dependent effect.
Dynamic Contrast Enhanced magnetic resonance
imaging (DCE-MRI) and histological analysis were
used to assess vessel morphology and function, and
Fluorine-18 Fluoromisonidazole (18F-FMISO) PET
was used to assess tumoural hypoxia.
The results presented here do not support the
hypothesis that bevacizumab treatment causes a transi-
ent window of normalisation of tumour vessels func-
tion during the early stages of treatment. Instead,
tumoural blood flow remained heterogeneous and inef-
ficient during the period analysed. Moreover,
18F-FMISO PET imaging showed a progressive
increase in hypoxia in bevacizumab treated tumours,
consistent with the reduced blood flow observed by
magnetic resonance imaging (MRI).
Materials and methods
Xenograft models
A total of 37 nude male or female adult rats (rnu-/rnu-
Rowett) were used for the studies (29 in the perfusion
study and 8 in the hypoxia study). Group sizes were
calculated according to expected variance in tumours
growth, on the basis of previous similar studies.
Animals were grouped in cages, fed ad libitum with
standard food pellets, and their welfare was monitored
through daily routine checks with increased daily fre-
quency as animals were approaching the end stage. We
used GBM spheroids generated from two different
patients, Patient 3 (P3) and Patient 13 (P13) as previ-
ously described.25 Tumour tissue was harvested during
surgery and subsequently serially transplanted orthoto-
pically in the animals. The tumours were passaged for
either 32 (P3) or 7 (P13) generations in vivo. Both these
models have been characterised in detail and recapitulate
patient GBMs features by showing vascular prolifer-
ation, diffuse tumour cell infiltration and pseudo-
palisading necrosis.26 They have the following genomic
characteristics; P3:þ [Chr 7, Chr19, 20q], - [1q42-q43,
Chr9, Chr10, 20p] – [PIK3R1, CDKN2A/B];
P13:þ [Chr7, Chr19, Chr20], - [6q16.2-16.3, Chr10,
17q12], – CDKN2A/B.27 P13 is a highly angiogenic
model with pronounced necrosis and little invasion. It
displays contrast enhancement on T1-weighted images
after injection of a gadolinium-based contrast agent,
and responds to bevacizumab by a strong reduction in
contrast enhancement. In comparison, P3, which is
angiogenic as well, is more invasive and displays a less
aggressive progression. It responds to bevacizumab by
reduced contrast enhancement too, and has also been
shown to increase glycolytic activity and invasion.23,24
Pimonidazole staining shows increased hypoxia after
bevacizumab treatment in both models. The key histo-
logical features of the P3 and P13 animal models are
summarised in online Supplementary Figure S1.
2 Journal of Cerebral Blood Flow & Metabolism
The collection of biopsy tissue was approved by the
regional ethical committee at the Haukeland University
Hospital, Bergen, Norway (REK 013.09).
Intracranial implantation
All animal experiments were performed within a facility
that was recently certified by the Association for
Assessment and Accreditation of Laboratory Animal
Care (AAALAC) International. All experiments were
done in accordance with the Norwegian Animal Act.
The protocols were approved by the Animal Welfare
Body of the University of Bergen, and are in compli-
ance with the ARRIVE guidelines (www.nc3rs.org.uk/
arrive-guidelines). P3 or P13 spheroids were implanted
stereotactically into the brains of nude immunodeficient
rats, as described previously.28 A burr hole was made
3mm lateral and 1mm posterior to the bregma on the
right side and the spheroids were injected 3.5mm below
the cortical surface. The animals were euthanized when
neurological signs were evident, by CO2 inhalation, and
perfused intracardially with 0.9% NaCl. The brains
were removed, the caudal half was fixed in formalin
and further processed for histological and immunohis-
tological examination.
Bevacizumab treatment
Treatment was initiated once the tumours reached an
average size of about 50mm3 as measured by MRI
(typically 3 weeks after implantation for P13 and 4
weeks for P3). Animals were then divided randomly
into treatment groups or controls. Bevacizumab
(Avastin, Genentech, San Francisco, CA, USA) was
injected i.v twice a week, at 10mg/kg (high dose) or
5mg/kg (low dose). The control animals received i.v
saline following the same schedule. Separate groups
of P13 implanted animals were used for the perfusion
MRI studies and the hypoxia PET studies. The generic
design of the studies is summarised in online
Supplementary Figure S2, together with the number
of animals used in each study.
Immunohistochemistry
Immunohistochemistry was performed as described
previously.24 Paraffin-embedded formalin-fixed tissue
sections were de-paraffinized and brought to a tempera-
ture of 99C for 20min using a 10mM citrate buffer at
pH 6.0 or incubated with proteinase K diluted in
0.05M Tris-Cl, at pH 7.5 and a temperature of 37C
for 10min. The following primary antibodies were used
during sections incubation: anti-von Willebrand factor
(vWf) (1:1000; A0082; DAKO; Oslo, Norway), pimo-
nidazole (1:200; Hypoxyprobe 9.7.11; HPI Inc;
Burlington, MA, USA) and anti-human nestin
(1:1000; MAB5326; Millipore; Billerica, MA, USA).
Incubation of primary antibodies lasted 90min at RT.
A biotinylated secondary antibody (Vector
Laboratories, Trondheim, Norway) was used for detec-
tion, amplified with Vectastain ABC Reagent (Vector).
Development of the sections was done with 303-diami-
nobenzidine (DAB, DAKO Cytomation), according to
the manufacturer’s instructions. Pictures were
obtained using a Nikon light microscope (Nikon
Eclipse E600) and Nikon imaging software (Nikon
NIS Elements v 4.11).
MRI
MRI was used to screen the animals after implantation
and randomly split them into treatment and control
groups according to tumour volumes. Extensive MRI
sessions, including perfusion series, were then con-
ducted longitudinally throughout the treatment.
Images were acquired on a 7T horizontal
PharmaScan (Bruker Biospin) using either a quadratic
volume coil or a four-channel surface coil designed for
rat brain imaging. Animals were placed prone in a
cradle and kept asleep with gas anaesthesia. We used
1–2% isofluorane mixed with 50% air for the first series
of experiments, then switched to 50% O2 or 1–3% sevo-
fluorane mixed with 100% O2, following an institu-
tional decision motivated by animals stability,
accelerated recovery, and unchanged blood flow and
oxygenation. To avoid introducing experimental bias,
groups compared within a study were always anesthe-
tised with the same gas at all time points throughout the
study. Body temperature was kept constant at 37C and
breathing was monitored throughout the scan sessions.
The following acquisition parameters were used: (1) T2-
weighted (T2w): method RARE, spatial resolution
(SR) 137 mm 137 mm 1000 mm, echo time (TE)
36ms, repetition time (TR) 3500ms, rare factor (RF)
8, averages (AVG) 3; (2) T1-weighted (T1w): method
RARE, SR 137 mm 137 mm 1000 mm, TE 9ms, TR
1000ms, RF 4, AVG 4; (3) Diffusion Weighted Imaging
(DWI): method DtiEpi, SR 125mm 125 mm
1000 mm, 3 directions, 6 b-values per direction from 0
to 1664 s/mm2; (4) Dynamic Contrast Enhanced
(DCE): method FLASH, SR 156mm 156 mm
1000 mm, TE 2.1ms, TR 8ms, FA 17, time resolution
0.7 s, total scan time 1204800, Contrast Agent 0.1mmol/
kg of Omniscan (GE Healthcare) injected intravenously
after 2500. The animals were scanned every other day for
8 days, and treatment was started after the first scan
(Day 1).
Analysis of the MRI data was performed in
Paravision 5.1 (Bruker Biospin) and with routines
custom developed in Matlab 2015b (MathWorks,
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MA, USA) and C. Specifically, the perfusion analysis
was based on the pharmacokinetic modelling of the
DCE-MRI data using the adiabatic approximation of
the tissue homogeneity model and blind deconvolution
arterial input functions (AIFs), as described previ-
ously,23,29 to separate the contributions of perfusion
and vessels permeability changes to tumour physiology.
The blind deconvolution AIFs were scaled so that a
value known from the literature (12.8mL/100mL for
the interstitial spaceþ plasma fraction) was achieved
for the reference tissue (left and right temporalis mus-
cles).23 Datasets that displayed poor signal-to-noise
ratio (SNR) as a result of sub-optimal experimental
conditions such as incomplete injection of the contrast
agent or excessive rat motion, were excluded from the
quantification. Tumour volume (TV) was defined as the
part of the tumour visible on MRI, and measured by
delineating tumour on consecutive 2D T2-weighted sec-
tions, multiplied by section thickness. Growth rate
(GR) was calculated using the TV measurement at the
first and last time points as GR¼ 100 log (TVf/TV0) /
(tft0), where TVf and TV0 are the tumour volumes
at the last and first time points, respectively, and tf 
t0 is the difference in days between the time points.
Tumour volumes are expressed in mm3 and GR in ‘%
per day’.
PET/CT imaging and data analysis
In vivo tumour hypoxia was evaluated by PET using in-
house produced 18F-fluoromisonidazole (18F-FMISO)
(ABX GmBH, Radeberg, Germany). PET/CT images
were acquired on a small-animal nanoScan PET scan-
ner (Mediso Medical Imaging Systems, Budapest,
Hungary). An activity of 30MBq (31.8 4.1) of
18F-FMISO was injected in the tail-vein and the rats
were left awake for 120min prior to a 30min acquisi-
tion scan (coincidence 1:5, normal count mode) as pre-
viously described.24 Animals were anesthetised with 3%
sevofluorane mixed in air throughout the scans, and
monitored for breathing and temperature. CT semi-
circular scans (50 kVp, 300ms, 480 projections) were
performed for anatomical reference and attenuation
correction of PET images. PET reconstruction was per-
formed by Nucline nanoscan (Mediso Medical Imaging
Systems) from list-mode using the following param-
eters: reconstruction algorithm Tera-Tomo 3D, full
detector model, 4 iterations/6 subsets, 1:3 coincidence
mode and a voxel size of 0.4mm.
The images were quantified using InterView Fusion
v3.01 (Mediso Medical Imaging Systems). A 3mm
sphere-shape volume of interest was placed in both
the tumour and the contralateral hemisphere to calcu-
late tumour-to-brain ratios using standard uptake value
(SUV) mean.
Statistics
Individual animals were used as observations when
assessing tumour volumes and tumour voxels were
used as observations when assessing perfusion param-
eters, to account for the heterogeneity within the
tumours. Mean values for each time point are reported
for the treated and control animals. A Student’s t-test
was used to assess the statistical significance of differ-
ences between groups, calculated in Matlab




Twenty-nine animals were used in the perfusion MRI
studies, split for both the P3 and P13 models into con-
trols versus treatment groups, as detailed in online
Supplementary Figure S2. MRI showed a continuous
growth in both tumour models during the time period
of 1–8 days, for both the controls and the bevacizumab
treated tumours in P13 implanted animals (Figure 1(a)
and (b)) and P3 implanted animals (Figure 1(e) and (f)).
Tumour volume progression during that time window
was exponential for all models and treatment groups
(Figure 1(c) and (g)). Quantification of tumour volumes
indicated a tendency toward lower growth rate in the
bevacizumab treated group compared to the controls
for the P13 model (12% 2% versus 16% 2% per
day) (Figure 1(d)). Changes were however not statistic-
ally significant for the small cohorts used. For the P3
implanted animals, the tendency toward smaller growth
rate in the treated animals was less pronounced
(12% 3% vs. 14% 4% per day) (Figure 1(h)), sug-
gesting a weaker response to bevacizumab at the onset
of treatment, possibly due to the less angiogenic and
more infiltrative nature of this model. The changes were
nevertheless not statistically significant either in the
cohorts used.
We also acquired DWI data at each time point and
calculated apparent diffusion coefficients (ADC), which
have previously been related to cellularity, to see if lon-
gitudinal changes in ADC could inform us on a pos-
sible increase of the infiltrative compartment of the
tumours. ADC was however stable for both tumour
models over the time period investigated and no statis-
tically significant changes were observed (data not
shown).
Morphological normalisation of tumour vessels
DCE-MRI was used to obtain quantitative values of
perfusion and vessel permeability parameters over
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Figure 1. Tumor size evolution: Representative cases of tumour evolution for the animals implanted with the angiogenic P13
phenotype, showing one control (a), and one animal treated with high doses of bevacizumab (b). Images represent T2 weighted MRI
acquisitions (top rows) and contrast enhanced T1 weighted MRI (bottom rows). Quantification of corresponding tumour volumes (c)
and growth rates (d) for P13 animals per group. Whiskers boxes show percentile 25, median and percentile 75 values. Representative
cases of tumour evolution for the animals implanted with the more infiltrative P3 phenotype, showing one control (e), and one animal
treated with high doses of bevacizumab (f). Quantification of corresponding tumour volumes (g) and growth rates (h) for P3 animals
per group. Tumour volumes show an exponential progression in all groups for P13 (c) and P3 (g) during the time window of
observation. Growth rates were higher for controls than for bevacizumab treated animals in both the P13 (d) and the P3 (h) tumour
models, and this difference was more pronounced for the more angiogenic P13 tumour model. Tumour volumes expressed in mm3
and growth rates in % per day. Animals per group: P13 Controls-5, P13 Bev high-5, P3 Controls-5, P3 Bev high-6. High dose: 10 mg/kg.
(Scale bars: SE).
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time, and to assess if anti-angiogenic therapy induces a
window of normalisation of tumour vessels for the two
GBM models used. For the more angiogenic model
(P13), high and low doses of bevacizumab were used
to further evaluate whether this putative normalisation
was associated with a dose-dependent effect. Mean
tumour values as well as tumoural (voxels) values
were examined to account for the spatial heterogeneity
of the parameters within the tumour.
We observed that tumour blood volume (Vb)
increased over time in the control (untreated) animals
for the angiogenic P13 model, as illustrated by one rep-
resentative animal in this group (Figure 2(a), top line).
This increase was less pronounced in the treated ani-
mals, whether given high doses (10mg/kg) or low doses
(5mg/kg) of bevacizumab (Figure 2(a), middle and
bottom lines). Quantification of the mean tumoural
Vb (Figure 2(b), top line) revealed a steady progression
over time in the control animals, and for the treated
animals a reduction first, followed by a steady progres-
sion. In comparison to controls, tumoural Vb mean
values in the treated animals were 39% and 46%
lower on Day 5/6 for the animals treated with 10mg/
kg doses of bevacizumab (Bev high) and those treated
with the 5mg/kg doses of bevacizumab (Bev low)
groups, respectively (p< 0.001). Histogram analysis of
tumoural Vb values distribution (Figure 2(b), bottom
line) showed a progressive increase in the fraction of
high Vb values (dark blue) compared to medium Vb
(hatched blue) and low Vb (light blue) values over
Figure 2. Tumoural blood volume evolution. (a) Illustrative maps of blood volume (Vb) evolution for animals implanted with the
highly angiogenic P13 tumour model, showing one control (top line) and two animals treated with respectively high and low doses of
bevacizumab (middle and bottom lines). (b) Quantification of tumour mean Vb for P13 animals (top line) and histogram analysis of
tumoural Vb values distribution (bottom line). In comparison to controls, animals treated with bevacizumab high or low doses, show a
reduced tumour mean Vb and a reduced fraction of high Vb values shortly after the start of the treatment, suggesting a normalisation
of blood vessel morphology. Similar results are observed for the less angiogenic more infiltrative P3 model (c and d), where the
normalisation window extends throughout the whole observation period. Vb expressed in absolute values of mL/100 mL of tissue.
Thresholds for the high, medium and low values (dark, hatched and light blue/red) were defined by the 75% and 25% percentiles of the
whole voxel population for the given tumour model. Animals per group: P13 Controls-5, P13 Bev high-5, P13 Bev low-5, P3 Controls-
7, P3 Bev high-7. Bev high: 10 mg/kg, Bev low: 5 mg/kg.
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time for the control animals. In the animals treated
with high or low doses of bevacizumab, a reduction
of the fraction of high Vb values was observed early
after the start of the treatment, suggesting a possible
morphological normalisation effect caused by the
treatment.
For the less angiogenic and more infiltrative P3
model, tumour Vb also increased steadily over time
for the control animals (Figure 2(c)), with mean
tumour Vb and distribution showing more fluctuations
(Figure 2(d)). For animals treated with high doses of
bevacizumab, the normalisation effect suggested by
progressive decrease of mean tumoural Vb and progres-
sive reduction of the fraction of high Vb values, lasted
throughout the whole observation period. In compari-
son to controls, mean tumoural Vb in the treated ani-
mals was 82% lower on Day 7/8 (p< 0.001).
The permeability of blood vessels was also assessed,
using the permeability surface (PS) area product par-
ameter that represents the product of the permeability
(leakiness) of vessel wall by the area of vessel wall.
Similarly to Vb, PS increased in the P13 control animals
(Figure 3(a), top line). Quantification of mean
tumoural PS (Figure 3(b), top line) revealed a sustained
progression of this parameter over time in this group,
with a progressive increased fraction of high PS values
(Figure 3(b), bottom line). For the animals treated
with bevacizumab, PS was more stable over time
Figure 3. Tumoural vessel permeability evolution. (a) Illustrative maps of the permeability surface area product (PS) evolution for
animals implanted with the highly angiogenic P13 tumour model, showing one control (top line) and two animals treated with
respectively high and low doses of bevacizumab (middle and bottom lines). (b) Quantification of tumours mean PS for P13 animals (top
line) and histogram analysis of tumoural voxels PS distribution (bottom line). In comparison to controls, animals treated with
bevacizumab high or low doses, show a reduced tumour mean PS and a reduced fraction of high PS voxels shortly after the start of the
treatment, again suggesting a normalisation of blood vessel morphology. For the less angiogenic, more infiltrative P3 model (c and d),
the normalisation window extends throughout the whole observation period. Datasets displaying poor SNR as a result of experi-
mental conditions, such as on Day 1 for the represented P3 Control (C), were not considered in the quantification. PS expressed in
absolute values of mL/min/100 mL of tissue. Thresholds for the high, medium and low values (dark, hatched and light blue/red) were
defined by the 75% and 25% percentiles of the whole voxels population for the given tumour model. Animals per group: P13 Controls-
5, P13 Bev high-5, P13 Bev low-5, P3 Controls-7, P3 Bev high-7. Bev high: 10 mg/kg, Bev low: 5 mg/kg.
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(Figure 3(a), middle and bottom lines). Quantification
of mean tumoural PS for the animals treated with
high doses of bevacizumab showed a reduction
first, followed by a steady increase (Figure 3(b), top
line), similar to what was observed for the tumoural
blood volumes (Figure 2(b), top line). In comparison
to controls, PS in this treatment group was 52%
lower on Day 5/6 (p< 0.001). The distribution of
tumoural PS (Figure 3(b), bottom line) showed a reduc-
tion of the high PS values fraction first, followed by
a steady increase, again suggestive of a transient
normalisation of this parameter following anti-
angiogenic therapy. This effect was less pronounced
for the animals treated with the low dose of
bevacizumab.
For the less angiogenic, more infiltrative P3 model
(Figure 3(c)), mean tumour PS also increased steadily
in the controls and was more stable for the animals
treated with high doses of bevacizumab (Figure 3(d),
top line). In comparison to controls, PS in the treat-
ment group was 82% lower on Day 7/8 (p< 0.001). The
distribution of tumoural PS values showed a progres-
sive increase of the fraction of high PS values in the
controls, and a more stable or slightly decreasing frac-
tion of high PS values in the bevacizumab treated ani-
mals (Figure 3(d), bottom line).
In many studies on brain tumour perfusion, Ktrans, a
parameter that represents the outflow of contrast agent
from the vascular compartment to the tissue is used, to
provide an indication of vessel permeability. It should
however be noted that Ktrans is also influenced by blood
flow. This makes interpretation of changes in this par-
ameter more complex, especially in studies involving
treatments with anti-angiogenic agents that are
known to interfere with vessel permeability. PS, on
the contrary, is independent of blood flow, such that
changes in PS more accurately reflect changes in the
permeability of blood vessels. Nevertheless, the longi-
tudinal changes in Ktrans in our study closely followed
those of PS (online Supplementary Figure S3). Thus,
changes in vessel permeability, when further used in the
text, can here indifferently be regarded as referring to
changes in PS or Ktrans.
Details of mean tumour Vb, PS and K
trans for all
time points are provided in online Supplementary
Tables S1 and S2, together with the ratio of values
for bevacizumab treated versus control animals and
associated p-values.
In summary, the longitudinal study on changes in
blood volume and vessel permeability parameters sug-
gests a morphological normalisation of the blood ves-
sels early after the start of the anti-angiogenic therapy,
whether given in high or low doses, for both the more
angiogenic and the less angiogenic, more infiltrative,
tumour phenotypes used in this study.
Functional normalisation of tumour vessels
For the P13 model, blood flow (F) fluctuated over time
in the tumours of the control animals (Figure 4(a), top
line), with a tendency of mean tumour F to slightly
increase over time (Figure 4(b), top line), and a progres-
sive increase of the high F voxels fraction (Figure 4(b),
bottom line). In the treated animal groups, tumour F
values fluctuated but to a lesser extent compared to
controls (Figure 4(a), middle and bottom lines). In
comparison to controls, animals treated with high
doses of bevacizumab showed a more stable but lower
increase in mean tumour F values (fluctuating
fromþ 47% to 6% during the observation window)
and the fraction of high F values increased slightly
(Figure 4(b)). For the animals treated with low doses
of bevacizumab, the mean tumour F values kept fluc-
tuating over time and also increased less than for the
controls. Mean tumour F ranged fromþ 47% to 39%
in comparison to controls (with varying p-values at
each time point) during the observation window. The
distribution of F values also fluctuated over time with
no clear evolutionary trend (Figure 4(b)).
For the P3 control animals (Figure 4(c), top line),
both the mean tumour F and the fraction of high
tumour F increased over time (Figure 4(d)). For the
animals treated with high doses of bevacizumab
(Figure 4(c), bottom line), mean tumour F values
remained stable over time and was significantly lower
than controls (down to 45% of controls on Day 7/8,
p< 0.001). The fraction of high F values remained con-
stant during the observation window (Figure 4(d)).
Details of mean tumour F for all time points are
provided in online Supplementary Tables S1 and S2,
together with the ratio of values for bevacizumab trea-
ted versus control animals and associated p-values.
We also quantified perfusion parameters in other
regions to verify the consistency of the results obtained.
Assessment of perfusion parameters in the contralateral
brain is challenging because an uncompromised BBB
results in limited leakage of the contrast agent and
poor SNR with the method used. Quantification results
in this region are therefore to be considered with cau-
tion. We thus additionally quantified perfusion param-
eters in the temporalis muscle where the SNR is much
higher. Overall F, Vb and PS remained stable and
homogeneous over time in the muscle. In comparison
to tumours, F and Vb had a similar range of values
while PS was higher in the muscles than in the tumours,
for both models. All perfusion parameters seemed unaf-
fected by the treatment in the muscles while they were
reduced in the treated tumours. In the contralateral
brain, F, Vb and PS also remained rather stable and
homogeneous over time and were not affected by the
treatment. Most parameters were significantly lower in
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the brain than in the tumours. A rigorous comparison
would however be hazardous given the somewhat unre-
liability of parameters estimation in this region with
poor SNR.
In summary, the results presented here demonstrate
that anti-angiogenic therapy causes a morphological
normalisation of blood vessels, evidenced by a statistic-
ally significant decrease in tumoural blood volume and
vessel permeability, early after the start of the treat-
ment. In this time window however, no functional nor-
malisation was observed in the tumours of the treated
animals that would have resulted in an improved
blood flow. Instead, tumoural blood flow remains het-
erogeneous over time, and shows no improvement in
comparison to the values observed for the control
animals.
Hypoxia
Eight animals implanted with the angiogenic model P13
were used in the PET study, split in controls versus
treatment group (bevacizumab high doses). Hypoxia
was assessed by 18F-FMISO PET. The signal obtained
with this tracer is indeed from hypoxic regions and not
healthy tissue since the tracer freely diffuses into all
tissues but is only trapped in hypoxic tissue. The opti-
mal timing between injection of the tracer and acquisi-
tion was determined from dynamic scans in pilot
studies. Longitudinal PET imaging with 18F-FMISO
on Day 1, 3, 7 and 12 after treatment start demon-
strated a slow increase of the tracer in the control
group (Figure 5(a), top line). The uptake of the tracer
was strikingly faster in the bevacizumab treated
Figure 4. Tumoural blood blow (F) evolution. (a) Illustrative maps of F evolution for animals implanted with the highly angiogenic P13
tumour model, showing one control (top line) and two animals treated with respectively high and low doses of bevacizumab (middle
and bottom lines). (b) Quantification of tumour mean F for P13 animals (top line) and histogram analysis of tumour F value distribution
(bottom line). In control animals, F is heterogeneous and shows a tendency to increase over time. For animals treated with high or low
doses of bevacizumab, F is not improved in comparison to controls and the distribution remains heterogeneous. Similar results can be
observed for the less angiogenic more infiltrative P3 model (c and d), suggesting that the morphological normalisation does not result
in a functional normalisation with improved and homogenous blood flow. F expressed in absolute values of mL/min/100 mL of tissue.
Thresholds for the high, medium and low values (dark, hatched and light blue/red) were defined by the 75% and 25% percentiles of the
whole voxels population for the given tumour model. Animals per group: P13 Controls-5, P13 Bev high-5, P13 Bev low-5, P3 Controls-
7, P3 Bev high-7. Bev high: 10 mg/kg, Bev low: 5 mg/kg.
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animals (Figure 5(a), bottom line), accelerating after a
few days of treatment. Quantification of the tracer
uptake (Figure 5(b)), using the tumour-to-brain ratio
of the mean SUV, further confirmed the results. The
poor oxygenation of the tumour evidenced here after
anti-angiogenic therapy is consistent with the poor
tumour perfusion and lack of functional normalisation
showed by MRI.
Discussion
As several clinical trials have shown no improvement in
OS after treatment of GBM with anti-angiogenic ther-
apy, the focus has now shifted to the identification of
the mechanisms of treatment resistance and potential
bio- and imaging markers for a subgroup of patients
that may respond to this therapy.
Traditionally, the proposed mechanism of action
of anti-angiogenic treatment was an inhibition of
tumour vessel growth, depriving the tumour of nutri-
ents and oxygen.12 The vascular normalisation hypoth-
esis emerged as an alternative mechanism of action,
through which normalised vessels would lead to an
improved blood flow and oxygenation of the
tumour.13,14
Our group has previously shown that anti-angio-
genic treatment with bevacizumab decreases contrast
enhancement and blood supply to the tumour in clin-
ically relevant GBM xenografts, increasing hypoxia
and invasion.23 These studies focused on the long-
term effects of the therapy, assessed after 3 weeks of
treatment with a dose of 10mg/kg given twice a week.
No information was provided then about the short-
term effects of the therapy and the possible existence
of a window of vascular normalisation early after treat-
ment. In the present work, we addressed this issue by
determining dynamic changes in brain tumour perfu-
sion parameters induced by bevacizumab over time,
assessed within the first week of treatment. We show
that, during this time window, bevacizumab treatment
tends to slow down tumour growth, with a more pro-
nounced effect in the purely angiogenic phenotype com-
pared to the mixed angiogenic/infiltrative phenotype.
This may reflect an initial treatment response, before
adaptation mechanisms occur. We have also previously
shown that bevacizumab treatment can lead to an up-
regulation of glycolysis, increased lactate accumulation
and invasion of tumour cells, possibly highlighting an
adaptation mechanism that enables a more infiltrative
tumour growth.23,24
Using DCE-MRI perfusion analysis, we show that
treatment with both high (10mg/kg) and low (5mg/kg)
doses of bevacizumab leads to a transient normalisa-
tion of the vessel morphology, evidenced by stable or
marginally decreased blood volume values, and further
confirmed this by immunohistochemistry and hist-
ology. The treatment also caused a strong decrease in
tumour vessel permeability parameters, evidenced by
the permeability surface area product PS and the
vessel-to-tissue transfer constant Ktrans that character-
ises the transport of contrast-agent across the capillary
endothelium.30 At the same time, blood flow did not
improve during the time window of the treatment, and
remained heterogeneous as evidenced by histogram
analysis. This suggests that the morphological normal-
isation of blood vessels induced by anti-angiogenic
therapy was not sufficient to achieve a functional nor-
malisation. The same results were achieved for the two
PDX used in the study, which have previously been
shown to display purely angiogenic or mixed angio-
genic/infiltrative phenotypes.31 Taken together, these
results suggest that poor tumour perfusion and reduced
vessel permeability after anti-angiogenic therapy are
likely to impede systemic drug delivery, possibly
explaining the disappointing results of combined anti-
angiogenic/chemotherapy regimens in the clinic so
far.5–7,10
The method used for perfusion analysis dictates
to a large extent the interpretation of putative
results obtained. Several reports on the effects of
Figure 5. Tumoural hypoxia evolution. (a) Representative
images of the longitudinal changes in hypoxia for P13 animals,
assessed 18F-FMISO PET, illustrate the high increased uptake of
this tracer following treatment with bevacizumab (high dose)
compared to the controls. SUV in arbitrary units. (b)
Quantification of the ratio of 18F-FMISO standard uptake value
(SUV) in tumour versus brain confirms these findings. The fol-
lowing numbers of animals were used (Controls: 4, Bev 10 mg/kg:
4). (Scale bars: SEM).
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anti-angiogenic therapy in the brain have used DSC-
MRI, a data acquisition method commonly used in
the clinic. This approach suffers from the limitation
that only relative perfusion parameters can be derived.
With this method, blood vessels are also assumed to be
non-leaky, such that pre-loading of contrast agent is
needed to compensate for the leakiness of blood vessels
typically observed in tumours. The contribution of
changes in the permeability of blood vessels to the
observed changes in blood flow is thus difficult to
appreciate with this method. DCE-MRI on the other
hand, provides absolute perfusion parameter estimates.
Most studies conducted with this method have been
based on the (extended) Tofts model for pharmacoki-
netic analysis, which also makes separation of blood
flow from vessel permeability parameter impossible.
DCE-MRI, based on the ATH pharmacokinetic
model as used in the present study, by introducing
one additional parameter in the analysis, makes it how-
ever possible to evaluate blood flow and vessels perme-
ability separately. This observation is of importance in
the context of treatment with anti-angiogenic agents
that are known to modulate the permeability of blood
vessels. More information on the methodology used for
perfusion analysis in this study is provided in the online
Supplementary material, together with examples of raw
signal curves and a discussion on the robustness of the
model.
Finally, whether DSC-MRI or DCE-MRI is used to
derive perfusion parameters maps, averaging blood
flow values over the whole tumour may also hide a
heterogeneous distribution of blood flow values that
would still result in poor perfusion of tumour
sub-regions. Histogram analysis of tumoural perfusion
parameters values makes it possible to capture this
heterogeneity dimension into the analysis, providing
additional information to parameters values averaged
over the whole tumour. Different studies have started
to recognise the role of using histogram and image fea-
tures analysis to account for the spatial heterogeneity of
tumours with benefits related to grading, prognosis and
assessment of therapy responses.32
In support of our results, a recent clinical study
showed no improvement in tumour oxygenation, des-
pite morphological vessel normalisation, assessed in
71 patients with recurrent GBM treated with bevacizu-
mab.33 Using 18F-FMISO PET to assess hypoxia, we
observed an increased uptake of the tracer both shortly
after treatment initiation, and during the first 12 days
of treatment, suggesting that the oxygenation of the
tumour was decreased rather than increased during
the first week of treatment. Poor tumour oxygenation
and hypoxia may also contribute to the poor perform-
ance of anti-angiogenic therapy combined with stand-
ard radio-chemotherapy regimens, by reducing the
efficacy of the radiotherapy part of standard GBM
treatment.
The observation that bevacizumab treatment
decreases contrast enhancement by normalising the
vessel morphology, despite the lack of benefit in OS,
has been considered of high clinical relevance, as it
identified the need for revised radiological response cri-
teria.8,34,35 Consequently, several studies have tried to
identify new radiological biomarkers to predict and
measure treatment responses. Schmainda et al.36
assessed changes in relative cerebral blood volume
(rCBV) by DSC-MRI and found that an early decrease
in rCBV was predictive of improved survival in patients
with recurrent GBM treated with bevacizumab. Other
studies have shown that pre-treatment rCBV is a poten-
tial predictive biomarker for bevacizumab treatment in
patients with recurrent GBM.30 It has also been pro-
posed that markers derived from diffusion weighted
MRI could be used to predict responses to anti-angio-
genic therapies.37,38 ADC has been shown to inversely
correlate with cellularity in the brain,39 providing a
potential indicator of infiltrative tumour progression.
Indeed, in the study we performed on the long-term
effects of bevacizumab,23 ADC was reduced in the per-
iphery of the tumours suggesting an increased tumour
cell infiltration, which was further confirmed by hist-
ology. In the present study, changes in ADC values in
the tumour periphery early after the start of the treat-
ment were only marginal, suggesting that the evolution
to a more infiltrative progression of the tumour is a
process that happens at a later stage, after an initial
adaptation to treatment.
The bevacizumab dose has also been discussed in the
context of vessel normalisation, as it was proposed that
lower doses may be more suitable to normalise vessels.
A recent meta-analysis revealed that there are no dif-
ferences in patient outcome whether treated with
10mg/kg or 5mg/kg,40 supporting our results in the
present study.
In conclusion, in our orthotopic GBM PDX models,
a transient functional window of normalisation of ves-
sels could not be identified following anti-angiogenic
therapy. Blood supply to the tumour remains heteroge-
neous and hypoxia increases while the permeability of
tumoural blood vessels is reduced, shedding a causal
light on the disappointing results of clinical trials
where anti-angiogenic therapies have been combined
with systemic delivery of chemotherapeutic agents.
This study also shows that MRI combined to PET
gives valuable insight into responses to anti-angiogenic
therapies, by assessing physiological changes in the
tumour in addition to the classically used morpho-
logical responses. Such a multimodal imaging approach
thus holds a great potential for assessing responses to
therapy in both pre-clinical and clinical research.
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